Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
EASD 2026
Effect of BMI on kidney-cardio outcomes with finerenone in a broad CKD population (INFINITY)
Higher baseline BMI was associated with a lower risk of kidney disease progression and a higher risk of CV events in participants with CKD.
The beneficial effects of finerenone vs placebo on the composite kidney outcome, composite kidney–CV outcome, CV events and all-cause death were consistent across the spectrum of baseline BMI values in this pooled population.
Incidence of adverse events and hyperkalaemia adverse events were similar across BMI categories. Hyperkalaemia was more common in the finerenone arm than placebo in all BMI categories, but serious events and events requiring hospitalisation were infrequent.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
